Sponsored by Castle Biosciences 

The Evolving Role of Gene Expression Profiling in Cutaneous SCC

The Evolving Role of Gene Expression Profiling in Cutaneous SCC

Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile

ReachMD Healthcare Image
Media formats available

One of the greatest challenges in managing cutaneous squamous cell carcinoma (cSCC) is determining which patients need more than surgery. For most patients, surgical treatment is sufficient. However, a certain subset of patients face an elevated risk of recurrence or metastasis. These high-risk patients may benefit from additional interventions, such as adjuvant radiation therapy, immunotherapy, or more intensive surveillance. Accurately identifying these high-risk patients is helpful in delivering appropriate, individualized care.

Traditionally, we have relied on established staging and risk-stratification systems, including those developed by Brigham and Women’s Hospital, the National Comprehensive Cancer Network, and the American Joint Committee on Cancer. Although these frameworks provide valuable guidance, they do not identify every patient at elevated risk.

Furthermore, some conventional prognostic features have inherent limitations. Histologic differentiation, for example, can be subject to interpretation and sampling variability. Similarly, perineural invasion is an important risk factor, but its absence in an examined specimen does not necessarily mean it is absent throughout the tumor.

Gene expression profiling (GEP) offers an additional dimension of risk assessment by providing objective, reproducible information about a tumor’s underlying biology. Rather than relying exclusively on clinical and histopathologic characteristics, GEP can reveal prognostic information that traditional risk factors may not capture.

The potential value of GEP extends beyond identifying patients who may benefit from treatment escalation. In appropriately selected patients, a lower-risk molecular profile may provide additional reassurance when considering whether more intensive interventions are necessary. Our goal should be to avoid both undertreatment and overtreatment.

In this supplement to Practical Dermatology, we will examine the growing body of evidence surrounding GEP testing in cSCC and explore how molecular insights can complement established risk-assessment tools. Ultimately, the objective is straightforward: to better identify patients who need additional care while sparing others unnecessary treatment and surveillance.     

- Brent Moody, MD, FACP, FAAD

SUMMARY

This study from Ruiz et al provides additional evidence that the 40-gene expression profile (40-GEP) test may help identify patients with high-risk cutaneous squamous cell carcinoma (cSCC) who are most likely to benefit from adjuvant radiation therapy (ART) following surgical resection. The 40-GEP test analyzes tumor gene expression and assigns one of three molecular classifications: Class 1, indicating low metastatic risk; Class 2A, indicating higher metastatic risk; and Class 2B, indicating the highest metastatic risk. Although the test was initially validated as a prognostic tool, emerging evidence suggests that it may also have predictive utility in identifying patients more likely to benefit from ART.

Ruiz et al conducted a retrospective study using primary cSCC tumors diagnosed between January 2011 and January 2022 at the Cleveland Clinic and Massachusetts General/ Brigham and Women’s Hospital. The analysis included 423 tumors from 399 patients who had at least one high-risk clinicopathologic feature and sufficient tissue available for 40-GEP testing. Of these tumors, 52 received ART and 371 did not. The median patient age was 76 years, approximately 70% were male, and 28.1% were immunosuppressed. Nearly half of the tumors occurred on the head or neck, and 74.7% were treated with Mohs micrographic surgery.

Of the 423 tumors, 228 (53.9%) were classified as Class 1, 168 (39.7%) as Class 2A, and 27 (6.4%) as Class 2B. Because ART was not randomly assigned, the researchers employed propensity score matching to reduce differences between treated and untreated groups. Matching incorporated age, immune status, tumor location, diameter, thickness, invasion beyond subcutaneous fat, perineural invasion, and surgical treatment. The researchers subsequently performed 10,000 iterations of random sampling and bootstrap resampling to compare metastatic progression between ART-treated and untreated tumors within each molecular classification.

Primary analyses examined 5-year metastatic progression rates and mathematically projected time to metastatic events. The strongest association between ART and improved outcomes occurred among patients with Class 2B tumors. The median 5-year metastatic progression rate across resampled cohorts was 60% among untreated Class 2B tumors, compared with 0% among ART-treated Class 2B tumors. Within matched cohorts, the median difference in 5-year progression rates for Class 2B tumors was 50 percentage points in favor of ART.

These estimates should not be interpreted as proof that ART completely eliminates metastatic risk in Class 2B patients. They represent modeled medians of metastatic risk derived from repeated sampling of a relatively small subgroup, including only eight ART-treated Class 2B tumors. Nevertheless, the magnitude and consistency of the observed difference support the possibility that Class 2B status identifies tumors particularly likely to benefit from postoperative radiation.

The analysis also demonstrated a substantial difference in projected time to metastatic events. For Class 2B tumors, the median projected time to metastatic predominance increased from 3.7 years without ART to 8.4 years with ART, a 2.4-fold difference. The distributions differed significantly between treated and untreated cohorts (P<0.01). These time estimates also were mathematical projections of when more than half of a modeled cohort would experience metastasis, not directly observed median times to metastasis.

At the opposite end of the molecular risk spectrum, Class 1 tumors demonstrated no statistically significant difference in metastatic progression between ART-treated and untreated groups. This finding is particularly relevant because Class 1 tumors represented more than half of the study population. The results suggest that patients with Class 1 tumors, especially those without additional concerning clinicopathologic characteristics, may be candidates for foregoing ART following complete surgical excision.

The authors emphasized that this decision should incorporate the patient’s overall clinical presentation. Particularly concerning features, such as lymphovascular invasion, may still justify additional treatment despite a Class 1 molecular classification. The lack of observed ART benefit in this subgroup supports using molecular information alongside conventional risk assessment rather than relying exclusively on staging classifications. Patients with Class 2A tumors initially appeared to demonstrate modest apparent benefit from ART. The median 5-year metastatic progression rate was 30.5% among untreated tumors compared with 12.5% among ART-treated tumors. The median projected time to metastatic predominance also increased from 6.4 years without ART to 7.9 years with treatment, a statistically significant difference (P<0.05). However, additional analyses suggested that the benefit may have depended on irradiation to proximal anatomic sites.

Among Class 2A tumors treated with ART, 37.5% received radiation to both the primary tumor bed and regional nodal basin. When investigators excluded tumors receiving nodal basin irradiation and repeated their analyses, the apparent Class 2A benefit disappeared. The difference in projected time to metastatic events decreased from approximately 1.5 years to 0.47 years and was no longer statistically significant. In contrast, the Class 2B benefit remained significant after excluding patients who received nodal irradiation.

These findings raise the possibility that Class 2A tumors may derive greater benefit from radiation fields incorporating regional lymphatics rather than the primary tumor bed alone. However, the authors cautioned that this hypothesis requires further investigation and should not be considered established evidence supporting routine nodal irradiation in Class 2A patients.

An important strength of the investigation is its independent confirmation of previously published findings. An earlier multicenter study by Arron and colleagues included 920 tumors and similarly reported an approximately 50% reduction in metastatic progression among Class 2B tumors receiving ART.1 Both studies also found no meaningful ART benefit among Class 1 tumors. The consistency of these findings across independent patient cohorts strengthens the argument that the 40-GEP test may offer information beyond conventional prognostic assessment.

DR. MOODY’S COMMENTARY

One of the most consequential decisions we face when managing patients with high-risk cutaneous squamous cell carcinoma (cSCC) is whether to recommend adjuvant radiation therapy (ART) following surgery. Even when we believe we have successfully removed a tumor, there may be concern about its potential to recur or metastasize. The question becomes whether that risk is sufficiently high to justify additional treatment.

This is not an uncommon clinical dilemma. We regularly encounter patients for whom the potential benefits of radiation must be weighed against the burdens of treatment. Ultimately, we must make a decision: either we recommend adjuvant radiation therapy, or we do not. There is no halfway approach.

GEP provides an additional tool to help us make that decision. The 40-GEP test offers objective information about the biological behavior of a tumor that may not be captured by traditional clinical and histopathologic risk factors.

The study by Ruiz et al provides important evidence regarding the potential value of 40-GEP testing in identifying patients most likely to benefit from ART and those for whom additional treatment may offer less benefit.

The study was designed to independently evaluate whether 40-GEP testing could distinguish patients with high-risk cSCC who were more or less likely to benefit from postoperative radiation. Investigators retrospectively analyzed primary cSCC tumors from patients treated at two academic medical centers. Tumors underwent 40-GEP testing, and outcomes were evaluated according to molecular risk classification and whether patients received ART.

The test categorizes tumors into three molecular risk groups: Class 1, representing lower risk; Class 2A, representing intermediate risk; and Class 2B, representing the highest risk.

The investigators used matched patient comparisons and repeated random sampling to evaluate differences in disease progression between patients who received ART and those who did not. The analysis included 52 ART-treated patients and 371 patients who had not received ART, with outcomes evaluated over 5 years.

The principal finding was that patients with Class 2B tumors appeared to derive the greatest benefit from receiving ART. Across the matched, resampled comparisons, ART-treated Class 2B patients experienced a median 50% reduction in 5-year disease progression rates compared with patients who did not receive radiation.

Patients with Class 2A tumors demonstrated a more modest apparent benefit that may be more associated to the radiation field applied rather than the innate radiosensitivity of the tumor, whereas Class 1 patients did not demonstrate a clear benefit from ART.

These findings suggest that molecular risk classification may help clinicians better distinguish patients for whom postoperative radiation is likely to provide meaningful benefit from those who may reasonably consider avoiding additional treatment.

In my clinical practice, one of the most valuable applications of GEP testing is helping determine which patients may benefit from adjuvant radiation therapy after surgery.

The Class 2B result is particularly important. This represents the highest-risk molecular classification, and the evidence suggests that these patients are more likely to benefit from additional treatment.

Even when surgery has been successful by conventional measures, a Class 2B result raises concern about the tumor’s underlying potential for disease progression. In my view, this is a powerful data point when considering ART.

What makes the result especially useful is that 40-GEP provides prognostic information independent of traditional staging systems. A Class 2B result may identify substantial biological risk that is not fully reflected in the clinical or histopathologic characteristics of the tumor.

For that reason, I consider Class 2B a significant signal favoring adjuvant radiation therapy, even in patients whose tumors have been completely excised.

The Ruiz study reinforces this perspective by demonstrating a substantial association between ART and reduced disease progression in the Class 2B population.

However, we should recognize that these findings come from a retrospective analysis. They provide likelihood of benefit information that is meaningful evidence to inform treatment decisions, but they do not establish that every Class 2B patient will benefit from radiation.

Equally important is what a Class 1 result may tell us. When discussing GEP testing, we often focus on identifying patients who need more intensive treatment. But one of GEP’s greatest potential advantages is helping us recognize selected patients who may not need that additional treatment.

The first thing we must acknowledge is that no available prognostic tool is perfect. We do not have a test or risk assessment system that can guarantee how an individual cancer will behave. A favorable GEP result does not mean a patient has zero risk of disease progression. That is an important distinction, particularly when we are considering withholding a treatment that might otherwise have been recommended.

Nevertheless, in the appropriate clinical situation, a Class 1 result may provide additional reassurance that the risk of progression is sufficiently low to consider deferring ART.

This is especially valuable when the decision is uncertain based on traditional risk factors alone.

For example, we may have a patient with a successfully excised tumor and certain concerning clinical or histopathologic features, but we remain unsure whether radiation would meaningfully improve the outcome. A Class 1 result can provide another piece of information to help guide that discussion. The Ruiz study supports this approach, finding no clear ART benefit among patients with Class 1 tumors.

That does not mean radiation should automatically be withheld from every Class 1 patient. Rather, it suggests that molecular risk assessment may help identify patients for whom deescalation is a reasonable consideration.

With appropriate counseling, patients may be comfortable accepting a small but nonzero risk of progression in exchange for avoiding the burdens of additional treatment.

The intermediate-risk Class 2A population presents a more nuanced picture. In the initial analysis, investigators observed a modest apparent benefit from ART among patients with Class 2A tumors. However, further analysis demonstrated that this finding was influenced by whether radiation included the regional lymph node basin.

When patients who received nodal irradiation were excluded, the apparent Class 2A benefit was no longer observed. This distinction is important because it suggests that the relationship between molecular risk classification and ART benefit may depend partly on the treatment delivered. For Class 2A patients, I would be particularly cautious about making treatment decisions based on the molecular result alone. These findings reinforce the importance of considering the full clinical picture, including conventional risk factors, surgical findings, and the proposed radiation treatment plan.

One point I believe is essential for clinicians using 40-GEP testing is that it should complement, rather than replace, traditional staging. I encourage clinicians treating cSCC to continue using an established staging or risk-stratification system, whether that is the Brigham and Women’s Hospital system, the American Joint Committee on Cancer system, or the NCCN framework. We should then add the GEP result to that assessment.

Traditional systems provide important information, but they do not identify every patient at elevated risk. Molecular profiling adds another dimension by examining tumor biology rather than relying exclusively on clinical and histopathologic characteristics. We are not abandoning what we have traditionally done. We are augmenting our ability to stratify risk and make more informed decisions.

The Ruiz study highlights what I consider to be the two principal opportunities associated with 40-GEP testing. First, it may help us identify patients with biologically aggressive tumors who stand to benefit from more intensive treatment, even after apparently successful surgery. Second, it may help us identify selected patients for whom additional treatment is unlikely to provide sufficient benefit to justify its burdens. Both are important.

Our objective should not simply be to treat more patients or fewer patients. It should be to provide the appropriate level of treatment for each individual patient.

Although additional prospective evidence would strengthen our understanding of how GEP-guided decisions affect patient outcomes, the available data provide useful information for clinical decision-making today.

By integrating molecular risk assessment with traditional staging, clinical judgment, and informed patient discussions, we can move toward a more individualized approach to managing high-risk cSCC—one that seeks to minimize both undertreatment and overtreatment.

Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free